
Equillium Inc (EQ) Stock Forecast & Price Target
Equillium Inc (EQ) Analyst Ratings
Bulls say
Equillium is supported by a compelling fundamental setup because EQ504 targets a biologically validated AhR pathway in ulcerative colitis, with human intestinal explant data showing dose-dependent CYP1A1 induction and a deep preclinical package across 14 models that supports barrier repair, anti-inflammatory signaling, and colon-targeted activity. The company’s lead program is differentiated by oral, colon-specific delivery and minimal systemic exposure, which helps address the safety tradeoffs that constrain S1P modulators, anti-TNFs, and JAK inhibitors while still targeting a large ~180K U.S. advanced-therapy UC population. Additional optionality comes from EQ302, but the investment case is anchored by EQ504 and could inflect further with Phase 1 initiation in mid-2026, biomarker data in 2Q27E, and a cash position of $61.3M funding operations into 2029.
Bears say
Equillium is a high-risk, early-stage biotechnology company whose value is heavily dependent on EQ504 producing clean Phase 1 evidence of target engagement and tolerability, yet the program has not entered human testing and the biomarker-to-efficacy bridge remains unproven. Its downside case is stark, with roughly $50M of residual cash translating to about $0.34 to $0.35 per share, while the need for a future $125M equity raise after positive data underscores meaningful dilution risk if results are negative or ambiguous. Even with $61.3M in cash as of March 31, 2026, competition from Azora Therapeutics, regulatory uncertainty, and persistent safety concerns such as PAH and class perception risk weaken the investment case.
This aggregate rating is based on analysts' research of Equillium Inc and is not a guaranteed prediction by Public.com or investment advice.
Equillium Inc (EQ) Analyst Forecast & Price Prediction
Start investing in Equillium Inc (EQ)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Equillium Inc (EQ) Forecast
Equillium Inc (EQ) Analyst Forecast & Price Prediction
Start investing in Equillium Inc (EQ)
Order type
Buy in
Order amount
Est. shares
0 shares